{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:49:42Z","timestamp":1794901782162,"version":"4.9.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.vhri.2026.101603","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:54:17Z","timestamp":1773453257000},"page":"101603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Eliciting a Willingness-to-Pay Threshold in Denmark: Analysis of Published Reimbursement Decisions"],"prefix":"10.1016","volume":"56","author":[{"given":"Niccol\u00f2","family":"Morgante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Grootendorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria B.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asger S.","family":"Paludan-M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2026.101603_bib1","series-title":"The Guidelines Manual","year":"2012"},{"key":"10.1016\/j.vhri.2026.101603_bib2","series-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","year":"2017"},{"key":"10.1016\/j.vhri.2026.101603_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2014.06.003","article-title":"Health economic data requirements and availability in the European Union: results of a survey among 10 European countries","volume":"4","author":"Skoup\u00e1","year":"2014","journal-title":"Value Health Reg Issues"},{"issue":"7","key":"10.1016\/j.vhri.2026.101603_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jval.2019.03.003","article-title":"A new method to determine the optimal willingness to pay in cost-effectiveness analysis","volume":"22","author":"Phelps","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vhri.2026.101603_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jval.2016.02.020","article-title":"On the estimation of the cost-effectiveness threshold: why, what, how?","volume":"19","author":"Vallejo-Torres","year":"2016","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.101603_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40273-022-01215-w","article-title":"Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service","volume":"41","author":"Russo","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vhri.2026.101603_bib11","article-title":"Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs","volume":"7","author":"Strand","year":"2022","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.vhri.2026.101603_bib12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","article-title":"Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness","volume":"33","author":"Svensson","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2026.101603_bib14","series-title":"Vol. 16: How to Detect and Handle Outliers","author":"Iglewicz","year":"1993"},{"issue":"2","key":"10.1016\/j.vhri.2026.101603_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/wics.147","article-title":"ggplot2","volume":"3","author":"Wickham","year":"2011","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"issue":"43","key":"10.1016\/j.vhri.2026.101603_bib16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.vhri.2026.101603_bib17","author":"Wickham"},{"key":"10.1016\/j.vhri.2026.101603_bib18","author":"Robin"},{"issue":"3","key":"10.1016\/j.vhri.2026.101603_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/bimj.200710415","article-title":"Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection","volume":"50","author":"Ruopp","year":"2008","journal-title":"Biom J"},{"issue":"3","key":"10.1016\/j.vhri.2026.101603_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14737167.2017.1330152","article-title":"Recent amendments to NICE\u2019s value-based assessment of health technologies: implicitly inequitable?","volume":"17","author":"Paulden","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9","key":"10.1016\/j.vhri.2026.101603_bib25","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40273-019-00810-8","article-title":"Severity-adjusted probability of being cost effective","volume":"37","author":"Versteegh","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2026.101603_bib27","author":"Danske Regioner"},{"key":"10.1016\/j.vhri.2026.101603_bib28","series-title":"Health Care Expenditures by Function, Provider, Price Unit","year":"2024"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:24:03Z","timestamp":1794572643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"alternative-id":["S2212109926000178"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101603","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eliciting a Willingness-to-Pay Threshold in Denmark: Analysis of Published Reimbursement Decisions","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101603"}}